According to a recently published report by Research Nester on “Hepatitis B Vaccine Market: Global Demand Analysis & Opportunity Outlook 2027” delivers detailed overview of the hepatitis B vaccine market in terms of market segmentation by type, by dose, by end users and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The global hepatitis B vaccine market is anticipated to record a CAGR of around 5.8% over the forecast period i.e. 2019-2027. The market is segmented by type, dose & end users. The market is segmented by type into single antigen hepatitis B vaccine and combination vaccines. The market is further segmented by dose into 3-dose schedule, 2-dose schedule and alternate schedule. On the basis of end user, the market is segmented into hospitals, clinics and others.

North America region is anticipated to capture maximum share in the market owing to increased prevalence of cases and improvements in the healthcare facilities in the region. Additionally, government is taking various initiatives to educate people and developing awareness among them. Asia Pacific is projected to witness significant growth during the forecast period. India and China are anticipated to be the fastest growing markets in the Asia Pacific region on account of huge investments by companies in these countries.

Increasing number of cases of hepatitis B infection is expected to drive the market growth at a significant rate. Additionally, improved healthcare facilities and innovations in some new type of medications with better efficiency is leading to an upliftment in the market growth. Companies identified across the value chain of the global hepatitis B vaccine market are getting into mergers & acquisitions, improving their R&D activities and launching new products to gain the competitive edge in the market and to retain their position in the market. Moreover, there is an increased focus on combination vaccines owing to their ability to confer protection against multiple causative agents and thus decreasing the cost incurred in packaging and administering individual vaccines.

Increased Government Initiatives Leading to Increased Awareness

Government is continuously working on decreasing the cases of hepatitis B and creating awareness among people. For instance, Ministry of Health and Family Welfare under Government of India, launched National Viral Hepatitis Control Program on the occasion of World Hepatitis Day, 28 July 2018 aiming to end viral hepatitis by 2030. These initiatives are driving the growth of the hepatitis B vaccine market during the forecast period.

However, high cost of vaccination and non-willingness among people pertaining to the high cost of treatment is expected to operate as a key restraint to the growth of the hepatitis B vaccine market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the hepatitis B vaccine market which includes company profiling of Sanofi Pasteur, Merck, GlaxoSmithKline, Human Biologicals Institute, LG Life Sciences, Kaketsuke, Dynavax Technologies, and Janssen Pharmaceuticals. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the hepatitis B vaccine market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.